EADO 2022 | Clinical trials investigating the management of immune-related adverse events

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, provides an overview of clinical trials investigating the management of immune-related adverse events. A Phase II clinical trial (NCT03999749) is exploring the combination of tocilizumab with ipilimumab and nivolumab to prevent toxicity and either maintain or increase benefit. Results are looking promising at reducing grade 3 or 4 toxicities, which are common with the addition of tocilizumab. Additionally, the response rate and overall-survival (OS) are showing to be at least as good, if not superior, to what has previously been demonstrated without tocilizumab. Dr. Weber believed the use of biomarkers are in the near future to predict which patients are most likely to develop grade 3 or 4 immune-related adverse events (AEs) to identify who should be given treatment. A signature has been defined using an autoantibody chip that aids in predicting which patients are most likely to develop immune-related AEs of grade 3 or 4 and could be used to identify patients for clinical trials so that patients who do not need treatment for AEs can avoid the unpleasant side effects. This interview took place at the EADO 2022 congress.